Waldman Reid Alexander sold $7.3M of MANE

Waldman Reid Alexander (Chief Executive Officer) sold 67,500 shares of Veradermics, Inc (MANE) at an average of $107.86 ($106.72–$111.28, $7.28M total) across 5 trades on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Waldman Reid Alexander
Published Aug 19, 2026, 1:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 1:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MANE
Neutral
medium confidence
Mentioned
$MANE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MANENeutralLow
01

Why it matters

This provides a fresh, timestamped datapoint on CEO selling activity (size, price range, and post-sale holdings), but it does not include new business performance, guidance, or regulatory developments.

02

Market read

A disclosed CEO sale of about $7.28M worth of MANE shares may influence short-term sentiment, but the 10b5-1 context limits fundamental read-through.

03

What to watch

Traders may overreact to insider sales; the key nuance here is the pre-arranged nature of the trades and the lack of accompanying operational or guidance news.

Relevance 5/10Novelty 5/10Timing: filed 2026-08-18 for an 2026-08-17 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Veradermics, Inc (MANE).

Company-level read

Ticker impact

$MANENeutralMedium confidence
Context

Veradermics CEO Waldman Reid Alexander sold about 67,500 MANE shares for roughly $7.28M under a 10b5-1 plan, per Form 4.

Expected impact

Likely limited immediate price impact; any reaction would be sentiment-driven and may fade as 10b5-1 context is known.

Evidence & confidence

The article provides the transaction size, price range, and confirms a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal, as this is company-specific insider activity with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity planning rather than bearish expectations.

Key entities

  • Veradermics, Inc

    Company whose CEO insider sale is disclosed on Form 4.

  • Waldman Reid Alexander

    Chief Executive Officer and director who sold shares.

  • 10b5-1 plan

    Pre-arranged plan noted as Yes, which typically reduces interpretive weight.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MANEHighAI 9/10

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first ora

HighAI 8/10

Why is Veradermics stock climbing today?

Veradermics Inc (MANE) stock rose 2.5% after reporting positive 12-month data from its Phase 2/3 Study 302 for VDPHL01, showing hair growth in men with mild-to-moderate pattern hair loss. Leerink Partners raised its price target to $150 from $135. The company plans to announce data from a female pattern hair loss study in 2027. The S&P 500 also surged 1.7% on a strong jobs report.

$MANEMedAI 8/10

Veradermics stock rises on 12-month hair growth trial data

Veradermics Inc (NYSE:MANE) shares rose 2.3% after releasing 12-month Phase 2/3 trial data for VDPHL01, an oral minoxidil formulation. Twice-daily treatment showed a 43.9 hairs/cm2 increase, while once-daily showed 29.7 hairs/cm2. 89.1% of twice-daily participants reported visible hair coverage improvement. The treatment was well-tolerated with no serious adverse events.

$MANEHighAI 8/10

Veradermics Reports Positive 12-Month VDPHL01 Study Results in Male Hair Loss

Veradermics reported positive 12-month results for VDPHL01 in male hair loss, showing increased hair counts and improved coverage. Twice-daily dosing saw 43.9 hairs/cm² growth, while once-daily had 29.7. The treatment was well-tolerated with no serious adverse events. According to the company, crossover participants from placebo also showed improvements after six months.